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Abstract Mildly oxidized low-density lipoprotein activates
platelets through lysophosphatidic acid (LPA). Hence, the
platelet-activating properties attributed to native low-density
lipoprotein (nLDL) might be caused by LPA contamination. We
show that nLDL enhances thrombin receptor-activating peptide
(TRAP)-induced fibrinogen binding to KIIbL3. The LPA receptor
blocker N-palmitoyl-L-serine-phosphoric acid did not affect
nLDL-enhanced fibrinogen binding induced by TRAP, but
reduced TRAP-induced binding. cAMP and inhibitors of protein
kinase C and Ca2+ rises completely blocked ligand binding by
TRAP and nLDL/TRAP. Inhibitors of p38MAPK and ADP
secretion interfered only partially. Blockade of Rho-kinase
increased ligand binding 2^3-fold. We conclude that nLDL
enhances TRAP-induced fibrinogen binding independent of
LPA. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Increased levels of native low-density lipoprotein (nLDL)
are related to an increased risk for atherosclerosis. Platelets
are key elements in the initiation of arterial thrombosis. At
physiological concentrations (0.6^0.9 g protein/l), nLDL sen-
sitizes platelets to natural agonists such as K-thrombin, colla-
gen and ADP [1^4]. The sensitization is slow (30 min or
more), however, and nLDL alone fails to trigger shape
change, integrin KIIbL3 activation, or secretion of granule con-
tents. Sensitization of platelets occurs through phosphoryla-
tion of p38 mitogen-activated protein kinase (p38MAPK) within
10 s with 1.0 g/l nLDL and within 10 min with 0.1 g/l nLDL
and results in cytosolic phospholipase A2 (cPLA2)-activated
arachidonic acid release, a precursor of thromboxane (TxA2)
formation [5]. At higher concentrations (3 g/l) and longer in-
cubation times (s 4 h), nLDL becomes an independent ini-
tiator of platelet activation triggering aggregation and secre-
tion [6]. Thus, depending on concentration and time, nLDL
synergizes with other activators or is an independent platelet
agonist.
At the early stages of atherosclerotic development, endothe-
lial cells become activated and bind monocytes and T-lympho-
cytes, which subsequently migrate through the endothelium
into the subendothelium. nLDL accumulation has been found
in these areas [7] and minimally modi¢ed LDL (mm-LDL) has
been shown to cause an increase of monocyte binding to the
endothelium [8]. nLDL also increases intracellular Ca2 levels
in endothelial cells. The Ca2 rises induce VCAM-1 expres-
sion and subsequent binding of monocytes to the endothelium
[9].
Particularly modi¢ed forms of nLDL are atherogenic, and
the potency of nLDL as a platelet activator increases upon
oxidative modi¢cation, leading to faster responses at lower
concentrations. Oxidized LDL (ox-LDL) enhances aggrega-
tion and secretion induced by K-thrombin and ADP [10,11]
or induces spontaneous aggregation, adhesion and serotonin
release [12^14].
The e¡ects of oxidatively modi¢ed LDL have been attrib-
uted to lysophosphatidic acid (LPA), which is generated dur-
ing oxidation of nLDL [15]. Human platelets possess a G-
protein-coupled receptor for LPA, which is a member of the
endothelial di¡erentiation genes (Edg) receptor family [16].
The LPA receptor responds to low concentrations of LPA
(EC50 of 18 nM) with platelet shape change [15,17]. At higher
concentrations (EC50V1.6 WM), LPA increases cytosolic Ca2
levels and activates Src family tyrosine kinases and the tyro-
sine kinase Syk, both pathways being independent of platelet
shape change [17].
During nLDL isolation, oxidation is prevented by ethylene-
diaminetetraacetic acid (EDTA). However, a minimal degree
of oxidation might be inherent to nLDL isolation procedures,
raising the possibility that nLDL lacks any platelet-activating
properties.
The present study addresses the question whether platelets
respond to nLDL, independent of LPA-mediated cell signal-
ing.
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2. Materials and methods
2.1. Materials
Prostacyclin (PGI2) was from Cayman Chemical, Ann Arbor, MI,
USA. Indomethacin was from Sigma, St. Louis, MO, USA. Iloprost
was from Schehring AG, Berlin, Germany. Bisindolylmaleimide I
(GF109203X), phosphoenolpyruvate (PEP) and pyruvate kinase
(PK) were all obtained from Boehringer Mannheim, Mannheim, Ger-
many. Bis-(o-amino-phenoxy)ethane-N,N,NP,NP-tetraacetic acid tetra-
kis(acetoxymethyl ester) (BAPTA-AM) was from Calbiochem Corpo-
ration, La Jolla, CA, USA. SB203580 was obtained from Alexis, San
Diego, CA, USA. N-palmitoyl-L-serine-phosphoric acid (L-NASPA)
was from Biomol, Plymouth, PA, USA. Rho-kinase inhibitor Y-27632
was kindly provided by Yoshitomi Pharmaceuticals, 3-7-25 Koyata,
Iruma-Shi Saitama, Japan. The thrombin receptor-activating peptide
SFLLRN (TRAP) was synthesized with a semi-automatic peptide
synthesizer (Labortec AG SP650, Switzerland) according to van
Scharrenburg et al. [18]. Fibrinogen was from Chromogenix, Mo«lndal,
Sweden, and made ¢brin- and ¢bronectin-free by passage through a
gelatin-Sepharose 4B column [19]. Sepharose 4B was from Pharmacia
Biotech, Uppsala, Sweden. FITC-conjugated anti-human ¢brinogen
was from DAKO, Glostrup, Denmark. All other chemicals used
were of analytical grade.
2.2. nLDL isolation
Fresh, non-frozen plasma from three donors, each containing less
than 200 mg lipoprotein(a)/l, was pooled and nLDL (1.019^1.063 kg/l)
was isolated by sequential £otation in a Beckman L-80 ultracentrifuge
[20]. To prevent bacterial contamination and lipid modi¢cation, 2 mM
NaN3 and 4 mM EDTA were present during each run (175 000Ug, 20
h, 10‡C). KBr was used for density adjustment. nLDL was dialyzed
against 103 volumes of bu¡er containing 150 mM NaCl, 1 mM EDTA
and 1 mM NaN3, and subsequently ¢ltered through a 0.45 Wm ¢lter.
Prior to each experiment, nLDL was dialyzed overnight against 104
volumes of 150 mM NaCl.
Levels of apoB100 were measured using the Behring Nephelometer
100. Possible oxidative modi¢cation was determined by monitoring
the formation of conjugated dienes at 234 nm of 50 mg apoB100/l
with 5 WM CuCl2W2H2O. The ¢nal nLDL preparation showed an
absorption at 234 nm of 0.26 þ 0.08. This was in the range of values
reported by Weidtmann [3] for nLDL isolated in the presence of
thimerosal (0.28 þ 0.04). All concentrations of nLDL are expressed
as g apoB100/l.
2.3. Isolation of human platelets
Human platelets were isolated from freshly drawn venous blood,
collected from healthy volunteers (with informed consent) into 0.1 vol
of 3.8% (wt/vol) trisodium citrate. The donors claimed not to have
taken any medication 10 days prior to blood collection. Platelet-rich
plasma was prepared by centrifugation (156Ug, 15 min, 20‡C). Then,
0.1 vol of ACD (2.5% trisodium citrate, 1.5% citric acid, 2% D-glu-
cose) was added to lower the pH of the plasma to 6.5 and thus
prevent platelet activation during further isolation. Platelets were fur-
ther puri¢ed by centrifugation at 330Ug for 15 min at 20‡C. The
platelet pellet was resuspended in HEPES^Tyrode bu¡er (145 mM
NaCl, 5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4, 10 mM
HEPES, pH 6.5) containing 5 mM D-glucose. PGI2 was added to a
¢nal concentration of 10 ng/ml and the washing procedure was re-
peated once. The platelet pellet was resuspended in HEPES^Tyrode
bu¡er pH 7.2 containing 5 mM D-glucose to a ¢nal concentration of
0.4U1011 platelets/l. Prior to the experiments, the platelets were left at
room temperature for at least 30 min to ensure a resting state.
2.4. Binding of ¢brinogen
A volume of 0.3 ml platelets was treated with the cyclooxygenase
inhibitor indomethacin (30 WM, 30 min, 37‡C) to prevent secondary
e¡ects from the TxA2-dependent signaling pathway. The platelets
were then incubated with various inhibitors followed by pretreatment
with nLDL (1.0 g/l, 30 min, 37‡C) or an equal volume of 150 mM
NaCl and subsequently stimulated with TRAP (15 WM, 5 min) in the
presence of ¢brinogen (1 WM, 2 min) at room temperature. Platelets
were ¢xed in phosphate-bu¡ered saline (PBS) containing 1% form-
aldehyde after a 64-min incubation period with FITC-conjugated
anti-human ¢brinogen (1:30 dilution of 1.4 g/l). Fibrinogen binding
to KIIbL3 was analyzed by £ow cytometry (FACScalibur, Becton
Dickinson).
2.5. Statistical analysis
Statistical analysis was performed using one-way ANOVA with
Dunnett’s multiple comparison test as post test. Results are expressed
as means þ S.D. from 5^10 experiments without inhibitors, and from
three experiments with inhibitors.
3. Results
Indomethacin-treated platelets were stimulated with nLDL,
TRAP or a combination of TRAP and nLDL, and ¢brinogen
binding to KIIbL3 was determined by £ow cytometry. nLDL
alone failed to induce ¢brinogen binding, but a 30-min pre-
incubation of platelets with nLDL enhanced the TRAP-in-
duced ¢brinogen binding (100%) with 55 þ 30% (Fig. 1). Since
recent ¢ndings indicate that mildly oxidized LDL (mox-LDL)
induces platelet activation via LPA [15], nLDL-enhanced
¢brinogen binding induced by TRAP was measured in the
presence of L-NASPA, a blocker of the LPA receptor. At 1,
10, 20, and 30 WM L-NASPA, TRAP-induced ¢brinogen
binding decreased to 67 þ 26%, 32 þ 11%, 47 þ 23%, and
54 þ 38%, respectively (P6 0.001, Fig. 2). Surprisingly, follow-
ing pretreatment with nLDL, ¢brinogen binding remained
undisturbed at 178 þ 27%, 133 þ 5%, 132 þ 8%, and 143 þ
34% at the respective L-NASPA concentrations (P = 0.19).
Thus, the LPA receptor functions in TRAP-induced signaling,
whereas the enhancement of TRAP signaling by nLDL ap-
pears independent of LPA or its receptor.
To evaluate the signaling steps involved in the e¡ect of
nLDL on TRAP-induced ¢brinogen binding, studies were
repeated with metabolic inhibitors known to interfere with
signal transduction in platelets. The cAMP-raising agent ilo-
prost, the protein kinase C (PKC) inhibitor bisindolylmale-
imide and the Ca2 chelator BAPTA-AM all abolished ¢brin-
ogen binding to KIIbL3 induced by TRAP alone or in
combination with nLDL (Table 1). Thus, low cAMP, a rise
in Ca2 and activation of PKC are prerequisites for TRAP-
induced KIIbL3 activation with and without nLDL. Only par-
Fig. 1. nLDL-enhanced ¢brinogen binding induced by TRAP. Indo-
methacin-treated platelets (0.4U1011/l) were preincubated with ve-
hicle (150 mM NaCl) or with 1.0 g/l nLDL for 30 min at 37‡C.
Subsequently, the platelets were stimulated without (150 mM NaCl)
or with 15 WM TRAP (5 min) in the presence of 1 WM ¢brinogen
(2 min) at room temperature. Platelets were ¢xed in PBS/1% formal-
dehyde 64 min after the addition of FITC-conjugated anti-human ¢-
brinogen (1.4 g/l ; dilution 1:30). Fibrinogen binding was analyzed
by £ow cytometry. Data are means þ S.D., n = 5^10.
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tial inhibition was found with SB203580, an inhibitor of
p38MAPK.
Mox-LDL induces platelet shape change via Rho/Rho-ki-
nase activation [21]. To study the involvement of Rho-kinase
in the LPA-induced signaling pathway to KIIbL3 activation,
the platelets were preincubated with Y-27632, a Rho-kinase
inhibitor. This treatment increased both TRAP-induced ¢-
brinogen binding and nLDL/TRAP-induced binding (Table
1).
Finally, studies were repeated with PEP (0.28 mM) and PK
(3 U/ml) to interfere with released ADP. This treatment re-
duced ¢brinogen binding induced by TRAP alone or with
nLDL almost 3-fold (Table 1). Thus, a major part of the e¡ect
of nLDL originates from stimulation of TRAP-induced dense
granule secretion.
4. Discussion
Recent data show that oxidation of nLDL is accompanied
by LPA formation. LPA is the activating ligand for platelet
shape change induced by mox-LDL [15]. The present study
shows that a potent inhibitor of the LPA receptor strongly
interferes with the TRAP-induced ligand binding to KIIbL3 but
has no signi¢cant e¡ect when platelets have been pretreated
with nLDL. Thus, nLDL activates platelets independent of
LPA-mediated signaling. This nLDL-dependent pathway is
sensitive to iloprost and inhibited by bisindolylmaleimide
and BAPTA-AM, indicating that it shares common steps in
signal transduction by TRAP and other platelet activators.
nLDL-induced activation is sensitive to an ADP removing
mixture, indicating that a major part of the activation origi-
nates from TRAP-induced ADP secretion. Hackeng et al. [22]
already showed that 1.0 g/l LDL enhances the collagen-in-
duced release of serotonin from about 20% to 40% of max-
imal secretion. Similar results were obtained with stirred sus-
pensions stimulated with TRAP.
Rho-kinase is involved in LPA-signaling pathways leading
to shape change [21]. To investigate the role of Rho-kinase in
LPA-dependent signaling to KIIbL3, the platelets were treated
with Y-27632. This Rho-kinase inhibitor caused an increase of
the ¢brinogen binding induced by TRAP or nLDL/TRAP by
2^3-fold. Activated Rho-kinase induces phosphorylation of
myosin light chain leading to interaction of the myosin head
with actin to form contractile actin/myosin bundles. Rho-ki-
nase also phosphorylates moesin, which subsequently medi-
ates the interaction of the actin/myosin bundles with the plas-
ma membrane [21]. The actin cytoskeleton appears to play a
role in regulating KIIbL3 function and interruption of actin
¢lament turnover in platelets by cytochalasin D enables a
substantial portion of KIIbL3 to bind soluble ¢brinogen [23].
Thus, the observed KIIbL3 activation after Rho-kinase inhibi-
tion might have been due to interruption of the cytoskeletal
organization.
nLDL activates KIIbL3 by a pathway involving activation of
p38MAPK resulting in cPLA2-mediated arachidonic acid re-
lease, TxA2 formation and further signaling via the TxA2
receptor [5]. In addition, nLDL also induces p125 focal adhe-
sion kinase (p125FAK) phosphorylation [24]. Both p38MAPK
and p125FAK phosphorylation are early events after LDL^
platelet contact [5,24]. So far, the role of p38MAPK was
thought to be restricted to the TxA2-dependent pathway.
The present study shows that p38MAPK also functions in
nLDL signaling in indomethacin-treated platelets. Incubation
with SB203580, which inhibits the activation of p38MAPK, only
partially reduced ¢brinogen binding to KIIbL3 induced by
TRAP or nLDL/TRAP. Four isoforms of p38MAPK (p38K,
p38L, p38Q and p38N) have been identi¢ed, which are 60^
70% identical in their amino acid sequence [25]. As
SB203580 only inhibits the p38K and the p38L isoforms [25],
p38K and/or p38L are involved in the TxA2-independent
Fig. 2. nLDL activates platelets independent of LPA/LPA receptor-
mediated signaling. Indomethacin-treated platelets were incubated
with vehicle (DMSO) or the LPA receptor blocker L-NASPA (1, 10,
20 or 30 WM) for 5 min at 37‡C. Prior to stimulation with TRAP
in the presence of ¢brinogen at room temperature, platelets were
pretreated with 1.0 g/l nLDL (closed bars) or 150 mM NaCl (open
bars) at 37‡C. Fibrinogen binding was determined as described in
the legend of Fig. 1. Data are means þ S.D., n = 5^10, for the inhibi-
tor n = 3.
Table 1
E¡ect of metabolic inhibitors on nLDL-enhanced ¢brinogen binding to KIIbL3
Inhibitor TRAP-induced ¢brinogen binding (%) Fibrinogen binding induced by nLDL/TRAP (%)




SB203580 51 þ 5 48 þ 8
Y-27632 172 þ 63 366 þ 201
PEP-PK 31 þ 9 56 þ 11
Indomethacin-treated platelets were preincubated with vehicle (150 mM NaCl), iloprost (1 WM, 2 min), bisindolylmaleimide (5 WM, 2 min),
BAPTA-AM (30 WM, 30 min), SB203580 (10 WM, 30 min), Y-27632 (10 WM, 30 min) or PEP-PK (0.28 mM PEP, 3 U/ml PK, 2 min) at 37‡C
prior to pretreatment with 1.0 g/l nLDL or 150 mM NaCl, and stimulation with TRAP in the presence of ¢brinogen at room temperature. Fi-
brinogen binding was determined as described in the legend of Fig. 1. Data are means þ S.D., n = 5^10, for the inhibitors n = 1 or n = 3.
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KIIbL3 regulation. However, SB203580 does not inhibit the
phosphorylation of the p38Q or the p38N isoform, which there-
fore might also play a role in this nLDL-signaling pathway.
Thus, nLDL induces another important signaling pathway
independent of TxA2 formation, in which p38MAPK seems to
be involved. Moreover, this signaling pathway is completely
insensitive for treatment with L-NASPA.
In conclusion, we have shown that nLDL, independent of
LPA, is able to enhance the activation of a TxA2-independent
signaling pathway in TRAP-stimulated platelets. ADP, re-
leased from the dense granules, seems to mediate the activa-
tion of the TxA2-independent signaling pathway in which rises
of Ca2, activation of PKC and p38MAPK and cAMP as an
inhibitor are involved. Platelets from familial hypercholester-
olemia patients have an increased sensitivity to agonists due to
increased levels of nLDL in the circulation [26]. Therefore,
studies that deepen our insights in the mechanisms by which
nLDL sensitizes platelets, might provide tools for therapeutic
intervention and reduction of cardiovascular complications.
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